Biosimilar Barriers Persist Despite Billions in Potential Cost Savings: Who is Benefitting?
Healio Rheumatology featured HSS rheumatologist Allan Gibofsky, MD, in an article about access to biosimilars for patients.
"It is a major concern that the potential benefits of biosimilar medications have not been trickling down to patients," said Dr. Gibofsky.
"The best way to pass the savings to the patient is to reduce the administrative hurdles for physicians," he advised.
According to Dr. Gibofsky, prescribers need to make patients aware of where costs are being saved.
Read the full article at healio.com [registration required].